Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors

Publisher： Karger

E-ISSN： 1423-0232|91|5|251-260

ISSN： 0030-2414

Source： Oncology, Vol.91, Iss.5, 2016-09, pp. : 251-260

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors

By  

CANCER, Vol. 121, Iss. 11, 2015-06 ,pp. : 1817-1826

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I Study of Two Schedules of Oral S-1 in Combination with Fixed Doses of Oxaliplatin and Bevacizumab in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 81, Iss. 2, 2011-09 ,pp. : 65-72

Karger

Access to resources Recommend Favorite

Phase I study of gemcitabine, cisplatin, and S‐1 combination therapy for patients with untreated advanced biliary tract cancer

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 22, Iss. 9, 2015-09 ,pp. : 669-674

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3481-3490

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Phase I Study of Combination Chemotherapy with Gemcitabine and Oral S-1 for Advanced Pancreatic Cancer

By  

Oncology, Vol. 69, Iss. 5, 2005-12 ,pp. : 421-427

Karger

Access to resources Recommend Favorite